Johnson & Johnson vs ProShares UltraPro S&P500 — how do they compare? Johnson & Johnson trades at $260.68 (market cap $626.09B), while ProShares UltraPro S&P500 trades at $154.8. The key difference: Johnson & Johnson pays a 2.06% dividend while ProShares UltraPro S&P500 pays none. Which is the better fit depends on your goals.
| JNJ | UPRO | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $267.24 | $155.10 |
52-Week Low | $172.78 | $89.29 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
UPRO trades at $154.38, down 0.39% on the day, while maintaining a bullish technical outlook with strong moving average signals. The leveraged ETF tracking the S&P 500 faces mixed sentiment as oscillators show neutral readings amid record market highs. Recent institutional activity includes Bay Colony Advisors establishing a new position, indicating professional interest despite valuation concerns in the broader market.
The ETF's performance remains tied to S&P 500 momentum, with technical strength supporting near-term upside potential. However, elevated RSI levels and market-wide valuation concerns present headwinds. The absence of traditional fundamental metrics for this leveraged product emphasizes its tactical rather than long-term investment nature.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →